TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01233752

Intervention type: DRUG
Intervention: morphine chlorhydrate
Description: The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an electronic pump (PCA) for 48h with morphine chlorhydrate to be used in boluses by 1 mg with a lock out of 5 mins, max dose 20 mg in 4 hours.~Moreover, ketoprofen will be prescribed 160 mg x 2 per day (ketorolac 30mg x 2) (in case of allergy acetaminophene 1g x 3 daily).~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the PCA infusion (T0) and the following 48h).

Intervention type: DRUG
Intervention: morphine chlorhydrate
Description: The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an electronic pump (PCA) for 48h with morphine chlorhydrate to be used in boluses by 1 mg with a lock out of 5 mins, max dose 20 mg in 4 hours.~Moreover, ketoprofen will be prescribed 160 mg x 2 per day (ketorolac 30mg x 2) (in case of allergy acetaminophene 1g x 3 daily).~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the PCA infusion (T0) and the following 48h).
Study: NCT02066077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral temporal MECT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral temporal MECT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral temporal MECT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The right temporal MECT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The right temporal MECT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral frontal MECT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral frontal MECT
Study: NCT02373007

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Scopinaro Surgery
Description: Classic Scopinaro Technique is a bariactric surgery that proposes the stomach will be divide in two parts: a proximal part and a distal part for performing horizontal gastrectomy. Differently what will happen in the Modified Scopinaro Surgery that will divide the stomach in two parts: a proximal part and a distal part for performing gastroplasty.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Scopinaro Surgery
Description: Classic Scopinaro Technique is a bariactric surgery that proposes the stomach will be divide in two parts: a proximal part and a distal part for performing horizontal gastrectomy. Differently what will happen in the Modified Scopinaro Surgery that will divide the stomach in two parts: a proximal part and a distal part for performing gastroplasty.
Study: NCT03691506

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic CIMT group
Description: Constraint Induced Movement Therapy (CIMT) is a new treatment technique that claims to improve the arm motor ability and the functional use of a paretic arm - hand. CIMT forces the use of the affected side by restraining the unaffected side. Child with hemiplegic cerebral palsy can learn to improve the motor ability of the more affected parts of their bodies and thus cease to rely exclusively or primarily on the less affected parts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified CIMT group
Description: Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
Study: NCT02419794

Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: endovascular treatment for acute ischemic stroke patients with large vessel occlusion
Study: NCT01410240

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Conventional hemostatic techniques, such as cautery and manual compression, will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOSEAL Hemostatic Matrix + Standard of care
Description: FLOSEAL will be applied topically to areas of the knee where bleeding is observed (e.g. cut bone surfaces, subcutaneous tissue, posterior joint capsule, synovial tissue, medial and lateral gutters, branches of the genicular vessels, and suprapatellar pouch) and will occur intraoperatively. Sufficient amounts of FLOSEAL will be applied quickly using the provided applicators, followed by immediate approximation with a damp gauze, lap pad or sponge for approximately 2 minutes.~+ Standard of care: conventional hemostatic techniques, such as cautery and manual compression, will be used
Study: NCT03235362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1706
Description: Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days in each period.
Study: NCT04348500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clazakizumab
Description: IV Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clazakizumab
Description: IV Infusion
Study: NCT00593606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application
Study: NCT01309750

Intervention type: RADIATION
Intervention: Small Bowel Transit Study
Description: Patients that are enrolled and consented in the study will be given 300ml of water containing 5 millicurie (mCi) of technetium-99m (Tc-99m) diethylenetriamine pentaacetate (DTPA). This nuclear tracer/water mix will either be drank orally or placed down a nasogastric tube to begin the study. The patient will have to have nothing else to eat or drink for the duration of the study. The patients will have a nuclear scan performed at 2, 4, and 6 hours after ingestion of the nuclear tracer.
Study: NCT03872141

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer
Description: Quantitative measures that include additional aspects of peripheral neuropathy, such as pain, thermal allodynia, numbness and tingling are needed. We propose to evaluate several pharmacodynamics biomarkers in patients before and during chemotherapy: changes in nerve conduction velocity and amplitude, quantitative sensory testing (QST), computer based cognitive assessment, and rate of drop-out from treatment. The tests from this list that best correlate with decreased CIPN would be added to EORTC QLQ-CIPN20 scores and will provide an early indication of CIPN and/or CICI.
Study: NCT03576209

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: healthy lifestyle program
Description: Participants (intervention group) are following a 12 week health promotion program. They will count daily steps by pedometers and participate in weekly organised walks (within socio-cultural organisation)
Study: NCT03235362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1706
Description: Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1706
Description: Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1706
Description: Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1706
Description: Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1706
Description: Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1705+YHR1706
Description: Subjects will receive multiple oral doses of YHR1705 + YHR1706 QD for 5 consecutive days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1705+YHR1706
Description: Subjects will receive multiple oral doses of YHR1705 + YHR1706 QD for 5 consecutive days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1705+YHR1706
Description: Subjects will receive multiple oral doses of YHR1705 + YHR1706 QD for 5 consecutive days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1705+YHR1706
Description: Subjects will receive multiple oral doses of YHR1705 + YHR1706 QD for 5 consecutive days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1705+YHR1706
Description: Subjects will receive multiple oral doses of YHR1705 + YHR1706 QD for 5 consecutive days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1705+YHR1706
Description: Subjects will receive multiple oral doses of YHR1705 + YHR1706 QD for 5 consecutive days in each period.
Study: NCT01003262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emergency Department Observation Protocol
Description: The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured, inpatient evaluation
Description: This is unstructured management by an inpatient medical team.
Study: NCT00480675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trochanteric bursa injection done under fluoroscopy with depomedrol and bupivacaine
Description: Depomedrol 60 mg + bupivacaine 2.5 ml

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trochanteric bursa injection with depomedrol and bupivacaine
Description: Trochanteric bursa injection done with sham x-ray and 60 mg of depomedroal and 2.5 ml bupivacaine using landmarks for guidance.
Study: NCT03324971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medications review
Description: Medications review. Elimination of all unnecessary prescription to cut down the number of medications to the least possible number.~This is in line with the best practice guidelines.
Study: NCT04011293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNCT19
Description: 0.5 to 4 x 10\^6 autologous CNCT19 transduced cells per kg body weight, with a maximum dose of 4 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion.
Study: NCT00080990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study: NCT03495115

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: A MRI uses a strong magnet to produce detailed pictures of the inside of your body.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RSI
Description: RSI is a technique that aims to improve the pictures produced during a MRI exam.
Study: NCT04480996

Intervention type: DRUG
Intervention: Drugs Responsible for Cognitive Side Effects
Description: identification of road traffic accidents associated with drugs responsible for psychomotor side effects
Study: NCT00998205

Intervention type: DRUG
Group type: OTHER
Intervention: Dobutamine stress echo (DSE)
Description: Dobutamine intravenous infusion would be undertaken starting at 10 micro-grams/kg per minute in three minute intervals increased to 20, 30, 40 or 50 micro-grams/kg per minute or to a peak heart rate response of at least 85% age predicted maximum heart rate.

Intervention type: DRUG
Group type: OTHER
Intervention: Atropine bolus
Description: If at the end of the Dobutamine protocol, there is inadequate heart rate response, intravenous atropine boluses of 0.5 milligrams (maximum 1.0 mg) would be used as needed to achieve a heart rate of at least 85% of age predicted maximum heart rate.
Study: NCT00080990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study: NCT03118245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AuraGain
Description: After anesthetic induction, AuraGain is inserted in children

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-gel
Description: After anesthetic induction, I-gel is inserted in children
Study: NCT02716363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotational Atherectomy by Rotablator
Study: NCT04470869

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phone call
Description: The relatives of both groups will be contacted by phone one month after the discharge of the ICU of the death, three month after, six month after and twelve month after. During these interviews the PTSD symptoms, the anxiety and depression symptoms, the complicated grief symptoms (in case of death) and the satisfaction about the ICU stay will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone call
Description: The relatives of both groups will be contacted by phone one month after the discharge of the ICU of the death, three month after, six month after and twelve month after. During these interviews the PTSD symptoms, the anxiety and depression symptoms, the complicated grief symptoms (in case of death) and the satisfaction about the ICU stay will be collected.
Study: NCT02485899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMN 190
Description: 300 mg Intracerebroventricular (ICV) infusion administered every other week for up to 240 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracerebroventricular (ICV) access device
Description: Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
Study: NCT00672282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: 150mg p.o. daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03497715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine
Description: Test 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine
Description: Test 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine
Description: Test 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine
Description: Test 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Sodium
Description: Test 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Sodium
Description: Test 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Sodium
Description: Test 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Sodium
Description: Test 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Test 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Test 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Test 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Test 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Nurofen)
Description: Reference 1
Study: NCT00050089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard ART vs Mega ART
Description: Standard therapy vs Intensified therapy
Study: NCT01147211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2206
Description: MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
Study: NCT01185054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ½ strength apple juice
Description: For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another fluid can be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pediatric Electrolyte
Description: For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another electrolyte maintenance fluid can be used. Fluids containing non-physiological concentrations of glucose and electrolytes (carbonated drinks, sweetened fruit juices, water) will be discouraged.
Study: NCT02398162

Intervention type: PROCEDURE
Intervention: Multi Blood Collections
Description: At baseline (the day of presentation to hospital), 2 weeks, 12 weeks and 1 year later.
Study: NCT03497715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Nurofen)
Description: Reference 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Nurofen)
Description: Reference 1
Study: NCT02398162

Intervention type: PROCEDURE
Intervention: Single Blood Collection
Description: On the enrollment day

Intervention type: PROCEDURE
Intervention: Single Blood Collection
Description: On the enrollment day
Study: NCT03317379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentorship
Description: Weekly meetings with a recovered peer mentor once per week. Dyads discuss eating disorder symptoms and how to overcome them.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social support mentorship
Description: Weekly meetings with a social support mentor who has not personally struggled with an eating disorder, once per week. Dyads engage in activities unrelated to the eating disorder (e.g., a movie, a community event, volunteer work).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Record use with mentor
Description: Recovery Record is a smart phone or web-based application designed to provide recovery support to eating disorder patients. Includes a number of features aimed to promote recovery, such as a meal tracking, prompts for completing meals/snacks, tracking for additional symptoms such as stress and mood, motivational messages, information about coping strategies, and capacity to share logged data with clinicians and mentors.
Study: NCT01287793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigecycline
Description: intravenous, 200 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigecycline
Description: intravenous, 50 mg, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: oral tablet, 400 mg, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mL 0.9% Sodium Chloride intravenous
Description: intravenous fluid, 100 mL, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.9% Sodium Chloride intravenous 100mL, single dose
Study: NCT03079505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 MG [Sprycel]
Description: Dasatinib (Sprycel) 100 milligram, once-daily (QD) will be given to 25 patients orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib 150mg oral capsule [Tasigna]
Description: Nilotinib (Tasigna) 300 milligram, twice-daily (BID) will be given to 25 patients orally
Study: NCT00488241

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zarzenda
Description: Topically applied daily for 2 weeks
Study: NCT03499574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dysphagia therapy using surface EMG as biofeedback
Description: 10 x 45 minute sessions over 14 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care may include the following Speech and Language Therapy interventions; assessment, review, therapy, patient/family education etc.. Dose will vary.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Usual care may include the following Speech and Language Therapy interventions; assessment, review, therapy, patient/family education etc.. Dose will vary.
Study: NCT04788030

Intervention type: OTHER
Intervention: Nerve reconstruction
Description: Nerve bridging with muscle-in-vein conduits
Study: NCT01244139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB033
Description: IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion dummy drug
Study: NCT00759824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin, cyclophosphamide, vindesine, valproic acid
Description: Adriamycin 45 mg/m² day 1 IV Cyclophosphamide 1 g/m² day 1 IV Vindesine 3 mg/m² day 1 IV Valproic acid 20-30 mg/kg/day from day -7 until the end of treatment, orally
Study: NCT04703803

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 1% lidocaine injection in trigger points
Description: The trigger point injection procedure with 1% lidocaine will be e (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention
Study: NCT03497715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Nurofen)
Description: Reference 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Wockhardt)
Description: Reference 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Wockhardt)
Description: Reference 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Wockhardt)
Description: Reference 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Wockhardt)
Description: Reference 2
Study: NCT05592977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-Oral Distalizing Device
Description: The inner bow (1.2mm) is a modified version of the inner part of a conventional face bow. Two hooks were soldered onto the inner bow distal to the lateral incisor teeth regions, and U loop at 1st premolar region, and bends acting as mesial stop will be bent in front of the maxillary first molars. The anterior component of the inner bow is 3 mm free from the labial surface of anterior teeth
Study: NCT01079247

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive transfusion threshold
Description: maintain hemoglobin at 7-8 g/dL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal transfusion threshold
Description: Maintain hemoglobin at 10-11 g/dL
Study: NCT02660515

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Additional wrist arthroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF